Market Place

Market Place

Market Place

Menu

Post Enquiry

Post Enquiry

PharmaCompass

Home

Market Place

Market Place

Search
All
API
FDF
Price
Services
Excipients
Enquiries

    Find

    • Active Pharmaceutical Ingredients Active Pharmaceutical Ingredients
    • Finished Drug Formulations Finished Drug Formulations
    • Price Price
    • Excipients Excipients
    • Services Services
    • Market Place Marketplace

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    Scorr-Insert
    X

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    A collaboration with SCORR Marketing

    Loading...

    All Data

    Filters Filter refresh
    ×
    FILTER DATA :
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            Upfront Payment filter
              refresh

              Product Type Full Screen

              Companies Full Screen

              Lonza Group

              • Deals

              Virtual BoothGlobal Pharmaceutical Dosage Solutions Company

              SWITZERLAND Switzerland

              Contact Supplier Contact Supplier

              Virtual Booth Virtual Booth

              BIO International Convention

              Participation Not Confirmed

              Update your events

              XORTX Appoints Lonza for GMP Manufacturing and Formulation of XRx-101 (Oxypurinol) for Coronavirus / COVID-19 Clinical Trials

              Contact the Supplier

              Lead Product(s): Oxypurinol

              Therapeutic Area: Infections and Infectious Diseases

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Xortx Therapeutics

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Agreement April 30, 2020

              Details:

              Lonza Pharma will be resposible for manufacturing of active pharmaceutical ingredient for XRx-101 and XRx-008 in response to support the drug development and clinical trial process for COVID-19.

              Relief Therapeutics

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              SWITZERLAND Switzerland

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              BIO International Convention

              Participation Not Confirmed

              Update your events

              Relief Therapeutics Drug Aviptadil Enters FDA Trial at University of Miami, to Treat COVID-19-induced Respiratory Distress

              Contact the Supplier

              Lead Product(s): Aviptadil

              Therapeutic Area: Infections and Infectious Diseases

              Highest Development Status: Phase II Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable April 07, 2020

              Details:

              The trial will enroll patients who are already on mechanical ventilation in the hopes that Aviptadil can decrease mortality in this condition and help to improve the condition of the patient’s lung.

              Relief Therapeutics

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              SWITZERLAND Switzerland

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              BIO International Convention

              Participation Not Confirmed

              Update your events

              Relief therapeutics and NeuroRx File FDA IND for Aviptadil to Treat COVID-19-induced Respiratory Distress

              Contact the Supplier

              Lead Product(s): Aviptadil

              Therapeutic Area: Infections and Infectious Diseases

              Highest Development Status: Phase II Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable March 26, 2020

              Details:

              In a previous trial of VIP for ARDS caused by sepsis, 7 of 8 patients on mechanical ventilation showed substantial improvement and 6 ultimately left the hospital alive.

              PharmaCompass__DigitalAd